Patents and trademarks
An active strategy
Egetis’ patents encompass products based on PLED compounds and associated treatment methods.
The company’s patent applications do not just cover the first products based on PLED compounds and the initial clinical application. They also cover a broad spectrum of other applications, such as production methods and formulations for Egetis’s products.
Egetis carefully monitors developments concerning its intellectual property rights in all relevant areas as well as competing technologies and companies. Egetis’ patent strategy for intellectual property rights has been developed in close, long-term cooperation with its external US patent attorney.
Egetis has had trademark protection for the trademark PledOx® since 2010, for Aladote® since 2015 and for Emcitate® since 2017.